Abstract
The heat shock proteins (Hsp), the family of molecular chaperons, are key proteins in protein folding and maturation. The client proteins of Hsp are critical in number of biological processes including cellular proliferation, differentiation, survival, metastasis, invasion, and angiogenesis. Thus, Hsp family becomes one of the desirable targets for cancer treatment. It has been demonstrated that Hsp overexpress in multiple myeloma and linked in poor prognosis and relapse. This chapter describes about the Hsp and their possible link with the pathogenesis of multiple myeloma. It addresses the advancement and challenges in the development of Hsp inhibitors.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- ADP:
-
Adenosine diphosphate
- Aha1:
-
activator of HSP90 ATPase activity 1
- ALT:
-
alanine aminotransferase
- Apaf-1:
-
apoptotic peptidase activating factor 1
- AST:
-
aspartate aminotransferase
- ATP:
-
adenosine triphosphate
- Bax:
-
Bcl-2-associated X
- Bcl-2:
-
B-cell lymphoma-2
- Cdc37:
-
cell division cycle 37
- Chip:
-
carboxy terminus of Hsc70 interacting protein
- Cns1:
-
tetratricopeptide repeat domain 4
- CR:
-
connecting linker region
- CTD:
-
C terminal domain
- ErbB:
-
epidermal growth factor receptor
- ER:
-
Estrogen receptor
- Her3:
-
erb-b2 receptor tyrosine kinase 3
- HIF-1α:
-
hypoxia inducible factor 1 subunit alpha
- Hip:
-
Hsc70-interacting protein
- Hop:
-
Hsp70-Hsp90 organizing protein
- HSF-1:
-
heat shock transcription factor-1, Hsp, heat shock proteins
- MAPK:
-
Mitogen-activated protein kinase 1
- MEEVD:
-
Met-Glu-Glu-Val-Asp motif
- Mek1/2:
-
mitogen activated protein kinase kinase
- MD:
-
middle domain
- NF-κB:
-
nuclear factor kappa-light-chain- enhancer of activated B cells
- NTD:
-
N terminal domain
- PP5:
-
protein phosphatase 5
- p23:
-
prostaglandin E synthase 3
- Smac:
-
second Mitochondria-derived activator of caspases
- Tom70:
-
translocase of outer mitochondrial membrane 70
- TPR:
-
tetratricopeptide repeat domains
- Unc45:
-
unc-45 myosin chaperone B
References
Argyriou AA, Iconomou G, Kalofonos HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112:1593–1599
Azad AA, Zoubeidi A, Gleave ME, Chi KN (2015) Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nat Rev Urol 12:26–36
Bailey CK, Budina-Kolomets A, Murphy ME, Nefedova Y (2015) Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma. Cancer Biol Ther 16:1422–1426
Bakthisaran R, Tangirala R, Rao CM (2015) Small heat shock proteins: role in cellular functions and pathology. Biochim Biophys Acta 1854:291–319
Banerji U, O’Donnell A, Scurr M et al (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152–4161
Born EJ, Hartman SV, Holstein SA (2013) Targeting HSP90 and monoclonal protein trafficking modulates the unfolded protein response, chaperone regulation and apoptosis in myeloma cells. Blood Cancer J 3:e167
Calderwood SK, Gong J (2016) Heat shock proteins promote cancer: it’s a protection racket. Trends Biochem Sci 41:311–323
Caplan AJ (2003) What is a co-chaperone? Cell Stress Chaperones 8:105–107
Cavaletti G, Jakubowiak AJ (2010) Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 51:1178–1187
Cavanaugh A, Juengst B, Sheridan K, Danella JF, Williams H (2015) Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer. Oncotarget 6:39821–39838
Chadli A, Felts SJ, Wang Q et al (2010) Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the co-chaperone p23. J Biol Chem 285:4224–4231
Chatterjee S, Burns TF (2017) Targeting heat shock proteins in cancer: a promising therapeutic approach. Int J Mol Sci 18:E1978
Chauhan D, Li G, Hideshima T et al (2003) Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood 102:3379–3386
Chauhan D, Li G, Auclair D et al (2004) 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating heat shock Protein-27. Apoptosis 9:149–155
Chen B, Piel WH, Gui LM, Bruford E, Monteiro A (2005) The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics 86:627–637
Ciglia E, Vergin J, Reimann S et al (2014) Resolving hot spots in the C-terminal dimerization domain that determine the stability of the molecular chaperone Hsp90. PLoS One 9:e96031
Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10:86–103
Colombo G, Morra G, Meli M, Verkhivker G (2008) Understanding ligand-based modulation of the Hsp90 molecular chaperone dynamics at atomic resolution. Proc Natl Acad Sci U S A 105:7976–7981
Cordonnier T, Bishop JL, Shiota M et al (2015) Hsp27 regulates EGF/beta-catenin mediated epithelial to mesenchymal transition in prostate cancer. Int J Cancer 136:E496–E507
Donnelly A, Blagg BS (2008) Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem 15:2702–2717
Duus J, Bahar HI, Venkataraman G et al (2006) Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma 47:1369–1378
Flandrin P, Guyotat D, Duval A et al (2008) Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones 13:357–364
Flint OP, Kwagh J, Wang FY et al (2009) Tanespimycin prevents bortezomib toxicity and preserves neuronal morphology in primary rat dorsal root ganglion cultures. Blood 114:1112–1112
Fortugno P, Beltrami E, Plescia J et al (2003) Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A 100:13791–13796
Georget V, Terouanne B, Nicolas JC, Sultan C (2002) Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 41:11824–11831
Gerecitano JF, Modi S, Rampal R et al. (2015) Phase I trial of the HSP-90 inhibitor PU-H71. J Clin Oncol 33:2537
Gibert B, Eckel B, Gonin V et al (2012) Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. Br J Cancer 107:63–70
Goetz MP, Toft D, Reid J et al (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078–1087
Guo F, Rocha K, Bali P et al (2005) Abrogation of heat shock protein 70 induction as a strategy, to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 65:10536–10544
Hawle P, Siepmann M, Harst A, Siderius M, Reusch HP, Obermann WM (2006) The middle domain of Hsp90 acts as a discriminator between different types of client proteins. Mol Cell Biol 26:8385–8395
Hieronymus H, Lamb J, Ross KN et al (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10:321–330
Holmes JL, Sharp SY, Hobbs S, Workman P (2008) Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 68:1187–1196
Jego G, Hazoume A, Seigneuric R, Garrido C (2013) Targeting heat shock proteins in cancer. Cancer Lett 332:275–285
Jhaveri K, Taldone T, Modi S, Chiosis G (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823:742–755
Kamal A, Thao L, Sensintaffar J et al (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407–410
Kumar S, Stokes J 3rd, Singh UP et al (2016) Targeting Hsp70: a possible therapy for cancer. Cancer Lett 374:156–166
Langdon SP, Rabiasz GJ, Hirst GL et al (1995) Expression of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res 1:1603–1609
Lee HW, Lee EH, Kim SH, Roh MS, Jung SB, Choi YC (2013) Heat shock protein 70 (HSP70) expression is associated with poor prognosis in intestinal type gastric cancer. Virchows Arch 463:489–495
Li CY, Lee JS, Ko YG, Kim JI, Seo JS (2000) Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation. J Biol Chem 275:25665–25671
Lianos GD, Alexiou GA, Mangano A et al (2015) The role of heat shock proteins in cancer. Cancer Lett 360:114–118
Liu S, Yuan Y, Okumura Y, Shinkai N, Yamauchi H (2010) Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth. Biochem Biophys Res Commun 394:297–302
Liu W, Vielhauer GA, Holzbeierlein JM et al (2015) KU675, a concomitant heat-shock protein inhibitor of Hsp90 and Hsc70 that manifests isoform selectivity for Hsp90alpha in prostate Cancer cells. Mol Pharmacol 88:121–130
Madamanchi NR, Li S, Patterson C, Runge MS (2001) Reactive oxygen species regulate heat-shock protein 70 via the JAK/STAT pathway. Arterioscler Thromb Vasc Biol 21:321–326
Magrane J, Smith RC, Walsh K, Querfurth HW (2004) Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J Neurosci 24:1700–1706
Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM (2000) The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 275:37181–37186
Massey AJ, Williamson DS, Browne H et al (2010) A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol 66:535–545
Mayer MP, Bukau B (2005) Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci 62:670–684
McCollum AK, TenEyck CJ, Sauer BM, Toft DO, Erlichman C (2006) Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res 66:10967–10975
McCollum AK, TenEyck CJ, Stensgard B et al (2008) P-glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res 68:7419–7427
Meyer P, Prodromou C, Hu B et al (2003) Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol Cell 11:647–658
Miyata Y, Nakamoto H, Neckers L (2013) The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des 19:347–365
Moulick K, Ahn JH, Zong H et al (2011) Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 7:818–826
Murphy ME (2013) The HSP70 family and cancer. Carcinogenesis 34:1181–1188
Nagai N, Nakai A, Nagata K (1995) Quercetin suppresses heat shock response by down regulation of HSF1. Biochem Biophys Res Commun 208:1099–1105
Nemoto T, Ohara-Nemoto Y, Ota M, Takagi T, Yokoyama K (1995) Mechanism of dimer formation of the 90-kDa heat-shock protein. Eur J Biochem 233:1–8
Nimmanapalli R, Gerbino E, Dalton WS, Gandhi V, Alsina M (2008) HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Br J Haematol 142:551–561
Okawa Y, Hideshima T, Steed P et al (2009) SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113:846–855
Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046–1060
Patwardhan CA, Fauq A, Peterson LB, Miller C, Blagg BSJ, Chadli A (2013) Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis. J Biol Chem 288:7313–7325
Piper PW, Millson SH (2011) Mechanisms of resistance to Hsp90 inhibitor drugs: a complex mosaic emerges. Pharmaceuticals (Basel) 4:1400–1422
Plescia J, Salz W, Xia F et al (2005) Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7:457–468
ProteinAtlas (2018) The human protein atlas (https://www.proteinatlas.org/)
Rajkumar SV, Kumar S (2016) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 91:101–119
Ramanathan RK, Egorin MJ, Eiseman JL et al (2007) Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 13:1769–1774
Ratzke C, Mickler M, Hellenkamp B, Buchner J, Hugel T (2010) Dynamics of heat shock protein 90 C-terminal dimerization is an important part of its conformational cycle. Proc Natl Acad Sci U S A 107:16101–16106
Reddy N, Voorhees PM, Houk BE, Brega N, Hinson JM, Jillela A (2013) Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies. Cl Lymph Myelom Leuk 13:385–391
Reikvam H, Nepstad I, Sulen A, Gjertsen BT, Hatfield KJ, Bruserud O (2013) Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opin Investig Drugs 22:551–563
Rerole AL, Jego G, Garrido C (2011) Hsp70: anti-apoptotic and tumorigenic protein. Methods Mol Biol 787:205–230
Richardson PG, Badros AZ, Jagannath S et al (2010) Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 150:428–437
Richardson PG, Chanan-Khan AA, Lonial S et al (2011a) Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Brit J Haematol 153:729–740
Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC (2011b) Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Brit J Haematol 152:367–379
Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC (2011c) Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 152:367–379
Saibil H (2013) Chaperone machines for protein folding, unfolding and disaggregation. Nat Rev Mol Cell Biol 14:630–642
Saluja A, Dudeja V (2008) Heat shock proteins in pancreatic diseases. J Gastroenterol Hepatol 23(Suppl 1):S42–S45
Seggewiss-Bernhardt R, Bargou RC, Goh YT et al (2015) Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer 121:2185–2192
Sidera K, Patsavoudi E (2014) HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov 9:1–20
Siegel D, Jagannath S, Vesole DH et al (2011) A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma 52:2308–2315
Solit DB, Ivy SP, Kopil C et al (2007) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13:1775–1782
Sreeramulu S, Gande SL, Gobel M, Schwalbe H (2009) Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed 48:5853–5855
Stiegler SC, Rubbelke M, Korotkov VS et al (2017) A chemical compound inhibiting the Aha1-Hsp90 chaperone complex. J Biol Chem 292:17073–17083
Stuhmer T, Zollinger A, Siegmund D et al (2008) Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 22:1604–1612
Teng Y, Ngoka L, Mei Y, Lesoon L, Cowell JK (2012) HSP90 and HSP70 proteins are essential for stabilization and activation of WASF3 metastasis-promoting protein. J Biol Chem 287:10051–10059
Usmani SZ, Chiosis G (2011) HSP90 inhibitors as therapy for multiple myeloma. Clin Lymphoma Myeloma Leuk 11(Suppl 1):S77–S81
Voll EA, Ogden IM, Pavese JM et al (2014) Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression. Oncotarget 5:2648–2663
Wayne N, Mishra P, Bolon DN (2011) Hsp90 and client protein maturation. Methods Mol Biol 787:33–44
Wei L, Liu TT, Wang HH et al (2011) Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-kappaB. Breast Cancer Res 13:R101
Wheatley SP, McNeish IA (2005) Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 247:35–88
Whitley D, Goldberg SP, Jordan WD (1999) Heat shock proteins: a review of the molecular chaperones. J Vasc Surg 29:748–751
Wong DS, Jay DG (2016) Emerging roles of extracellular Hsp90 in cancer. Adv Cancer Res 129:141–163
Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S (2017) Heat shock proteins and cancer. Trends Pharmacol Sci 38:226–256
Yang X, Wang J, Zhou Y, Wang Y, Wang S, Zhang W (2012) Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells. Cancer Lett 321:137–143
Yenari MA (2002) Heat shock proteins and neuroprotection. Adv Exp Med Biol 513:281–299
Yokota S, Kitahara M, Nagata K (2000) Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res 60:2942–2948
Yu Z, Zhi J, Peng X, Zhong X, Xu A (2010) Clinical significance of HSP27 expression in colorectal cancer. Mol Med Rep 3:953–958
Zagouri F, Bournakis E, Koutsoukos K, Papadimitriou CA (2012) Heat shock protein 90 (hsp90) expression and breast cancer. Pharmaceuticals (Basel) 5:1008–1020
Zhang L, Fok JH, Davies FE (2014) Heat shock proteins in multiple myeloma. Oncotarget 5:1132–1148
Zhang Y, Tao X, Jin G et al (2016) A targetable molecular chaperone Hsp27 confers aggressiveness in hepatocellular carcinoma. Theranostics 6:558–570
Zuehlke A, Johnson JL (2010) Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 93:211–217
Acknowledgements
Authors are thankful for the proofreading and editing services of Cooper Medical School of Rowan University.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kale, V.P., Phadtare, S., Amin, S.G., Pandey, M.K. (2019). Targeting Heat Shock Proteins in Multiple Myeloma. In: Asea, A., Kaur, P. (eds) Heat Shock Proteins in Signaling Pathways. Heat Shock Proteins, vol 17. Springer, Cham. https://doi.org/10.1007/978-3-030-03952-3_12
Download citation
DOI: https://doi.org/10.1007/978-3-030-03952-3_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-03951-6
Online ISBN: 978-3-030-03952-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)